MaxWell Biosystems

About:

MaxWell Biosystems provides solutions to advance basic neuroscience research and accelerate preclinical drug discovery.

Top Investors: Venture Kick, EASME - EU Executive Agency for SMEs, Technology Fund, Sensirion

Description:

MaxWell Biosystems provides solutions to advance basic neuroscience research and accelerate preclinical drug discovery. Its product MaxOne, electrophysiology platform for recording and stimulating electrogenic cells in vitro. It is a CMOS-based high-density microelectrode array with 26,400 electrodes, 1024 low-noise readout channels, and 32 stimulation channels. It allows extracting single cell and network parameters that facilitate phenotypic screening and drug toxicity/efficacy testing.

Total Funding Amount:

$4.73M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Basel, Basel-Stadt, Switzerland

Founded Date:

2016-01-01

Contact Email:

info(AT)mxwbio.com

Founders:

Urs Frey

Number of Employees:

11-50

Last Funding Date:

2021-12-10

IPO Status:

Private

Industries: